跳至主要内容
临床试验/IRCT20161228031626N6
IRCT20161228031626N6尚未招募2 期

The effectiveness of adding modafinil drug on negative symptoms of schizophrenic patients being treated with risperidone or olanzapine

Ahvaz University of Medical Sciences0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Patients diagnosed with schizophrenia based on DSM-5 criteria
  • Schizophrenic patients who have been treated with risperidone or olanzapine.

排除标准

  • Taking typical antipsychotic and atypical antipsychotic drugs, except for risperidone and olanzapine, and antidepressants, sodium valproate, lithium, and benzodiazepines.
  • The presence of accompanying psychiatric disorders such as schizoaffective or other psychotic disorders, bipolar disorder, anxiety disorders such as panic disorder or obsessive-compulsive disorder, post-traumatic stress disorder, eating disorder
  • Dependence or abuse of substances, drugs or alcohol, acutely or in the past 12 months, except for nicotine
  • Allergy to Modafinil or any of the placebo ingredients

研究者

相似试验